Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Income from Continuing Operations (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Income from Continuing Operations for 7 consecutive years, with 7985.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 68.27% year-over-year to 7985.0, compared with a TTM value of 22483.0 through Sep 2025, up 117.42%, and an annual FY2024 reading of 131498.0, down 12.05% over the prior year.
  • Income from Continuing Operations was 7985.0 for Q3 2025 at Goldenwell Biotech, down from 5220.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 70065.0 in Q4 2024 and bottomed at 920334.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 68738.16, with a median of 27084.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 16234.25% in 2021, then soared 436.87% in 2024.
  • Year by year, Income from Continuing Operations stood at 29554.0 in 2021, then tumbled by 3014.08% to 920334.0 in 2022, then surged by 97.74% to 20799.0 in 2023, then skyrocketed by 436.87% to 70065.0 in 2024, then crashed by 111.4% to 7985.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for GWLL at 7985.0 in Q3 2025, 5220.0 in Q2 2025, and 34377.0 in Q1 2025.